ALAlnylam Pharmaceuticals ALNY · NASDAQ
$174.00 -25.13% (-$58.40)
- Market cap
- $23.3B
- Enterprise value
- $22.8B
- P/E
- 28.8x
- Forward P/E
- 26.6x
- PEG
- -
- P/S
- 4.8x
- P/FCF
- 42.9x
- EV/EBITDA
- 19.9x
- ROIC
- 25.6%
- Gross margin
- 79.7%
- Net margin
- 16.8%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -0.4x
- Beta
- 0.27
- Free float
- 99.6%
About the company
Alnylam Pharmaceuticals, Inc. is an American biotechnology company headquartered in Cambridge, Massachusetts. It focuses on the development of RNA-based therapeutics for the treatment of genetic diseases. The company specializes in RNA interference (RNAi) technology, which allows for the suppression of specific genes expression to treat genetic diseases at the gene level. Their research and development efforts target the treatment of various genetic diseases, including liver, kidney, muscle, and nervous system disorders. Alnylam Pharmaceuticals is known for its innovative approach to RNAi research and development of therapeutic agents for the treatment of rare diseases. The company collaborates with academic institutions, biotechnology firms, and pharmaceutical companies worldwide. Shares of Alnylam Pharmaceuticals, Inc. are publicly traded on the NASDAQ stock exchange.
Sector
Healthcare
Industry
Biotechnology
CEO
Yvonne L. Greenstreet
Employees
2,500
Headquarters
Cambridge
Valuation
Is today's price reasonable?
- What to watch: The share price is above the Bulios Fair Price.
Growth and estimates
Is it growing, and what comes next?
- What speaks for it: Revenue grew by 53% a year over the last 3 years.
- What to watch: Earnings per share swing sharply from year to year.
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
- What speaks for it: Out of every 100 USD of revenue, 17 USD is left as net profit.
- What speaks for it: It earns 26 USD a year on every 100 USD of invested capital.
Financial health
Can it carry its debt?
- What speaks for it: It holds more cash than debt: $1.75B against $1.26B.
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number